Hair loss was reported by a small share of people in tirzepatide's obesity trials, more often than in the placebo groups, and alopecia is listed as an adverse reaction on the Zepbound label. The pattern most researchers point to is not the drug attacking hair directly but the shedding that often follows rapid weight loss, a temporary type called telogen effluvium.
Reviewed for accuracy · Last reviewed July 8, 2026In SURMOUNT-1, the large obesity trial of tirzepatide, alopecia was reported by a few percent of participants and was more common on tirzepatide than on placebo, with the effect concentrated in women. It was not one of the frequent side effects, which were mostly gastrointestinal, but it appeared often enough to be listed. The Zepbound prescribing information includes alopecia among its adverse reactions.
Telogen effluvium is a well-recognized reaction to physical stress, including rapid or substantial weight loss and lower calorie intake, regardless of how the weight comes off. It pushes more hair follicles into a shedding phase, and the hair typically regrows over months once the body stabilizes. Because tirzepatide produces large, fairly quick weight loss for many people, this mechanism fits the trial pattern better than a direct drug effect on hair.
That framing comes with uncertainty. The trials record that hair loss happened, not why, so the weight-loss explanation is the most supported interpretation rather than a proven cause. Adequate protein and overall nutrition during weight loss are commonly suggested as sensible general measures, though that is not specific tirzepatide advice.